Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Service...(anufacturing servicesthroughout the drug...)

Date:6/24/2008

anufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle time and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .

About Covance

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 20 countries, and more than 8,900 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at http://www.covance.com.

Statements contained in this press release, which are not historical facts, such as statements about the nature, scope and timing and benefits of the planned joint venture as well as the attractiveness of China for delivering outsourced discovery and development services, the growth of the China market and advantages of conducting preclinical research and development in China are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein are based largely on Covance and WuXi PharmaTech management's expectations and actual results could vary significantly. The memorandum of understanding is non-binding and subject to negotiation of definitive documentation. The nature, scope and timing of the venture could change and definitive arrangements may not be agreed to by the parties. Success of the venture and the attractiveness of China, including for delivering outsourced discovery and development services, are subject to other risks and uncertainties including, without limitation, co
'/>"/>

SOURCE Covance Inc. Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related biology technology :

1. Covance to Present at The R.W. Baird 2008 Growth Stock Conference
2. Covance to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
4. Covance Inc. Invites You to Join the Webcast of Its Third Quarter 2007 Financial Results Conference Call
5. WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
6. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
7. WuXi PharmaTech Announces First Quarter 2008 Results
8. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
9. WuXi PharmaTech Schedules First Quarter 2008 Earnings Release on Tuesday, May 27, 2008
10. WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
11. Quest PharmaTech Receives Support from National Research Councils Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer